IMMUNE NETWORK
- Volume 3 Issue 4
- /
- Pages.302-309
- /
- 2003
- /
- 1598-2629(pISSN)
- /
- 2092-6685(eISSN)
Immunotherapeutic Effects of CTLA4Ig Fusion Protein on Murine EAE and GVHD
마우스 EAE, GVHD 질환에서 CTLA4Ig 융합단백의 면역치료 효과
- Jang, Seong-Ok (Asan Institute for Life Sciences) ;
- Hong, Soo-Jong (Department of Pediatrics, Asan Medical Center, Ulsan University) ;
- Cho, Hoon-Sik (Department of Microbiology, Hanyang University College of Medicine) ;
- Chung, Yong-Hoon (Department of Microbiology, Hanyang University College of Medicine)
- Published : 2003.12.30
Abstract
Background: CTLA4 (CD152), which is expressed on the surface of T cells following activation, has a much higher affinity for B7 molecules comparing to CD28, and is a negative regulator of T cell activation. In contrast to stimulating and agonistic capabilities of monoclonal antibodies specific to CTLA-4, CTLA4Ig fusion protein appears to act as CD28 antagonist and inhibits in vitro and in vivo T cell priming in variety of immunological conditions. We've set out to confirm whether inhibition of the CD28-B7 costimulatory response using a soluble form of human CTLA4Ig fusion protein would lead to persistent inhibition of alloreactive T cell activation. Methods: We have used CHO-